Click Here for 5% Off Your First Aladdin Purchase!

Voxelotor (GBT440) - 98%, high purity , Hemoglobin HbA positive modulator, CAS No.1446321-46-5, Hemoglobin HbA positive modulator

  • Moligand™
  • ≥98%
Item Number
V414047
Grouped product items
SKUSizeAvailabilityPrice Qty
V414047-2mg
2mg
In stock
$17.90
V414047-5mg
5mg
In stock
$35.90
V414047-25mg
25mg
In stock
$147.90
V414047-50mg
50mg
In stock
$246.90
V414047-100mg
100mg
In stock
$444.90
V414047-250mg
250mg
In stock
$1,001.90
V414047-500mg
500mg
In stock
$1,533.90

Basic Description

SynonymsVoxelotor|1446321-46-5|Oxbryta|GBT440|GBT 440|GBT-440|GTX-011|Hemoglobin Modulators-1|2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde|Voxelotor [USAN]|3ZO554A4Q8|GBT-440(Voxelotor)|2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR, POSITIVE MODULATOR
Mechanism of actionHemoglobin HbA positive modulator
Product Description

Information

Voxelotor (GBT440, GTx011) is a novel small moleculehemoglobin modifierwhich increases hemoglobin oxygen affinity.


In vitro

GBT440 is a new potent allosteric effector of sickle cell hemoglobin that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. GBT440 inhibits these isozymes(CYP 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4) with IC50 ranging from 7.9 to 148 μM. It is not a substrate for either P-gp or BCRP transporters It binds to the N-terminal a chain of Hb


In vivo

GBT440 has favorable oral bioavailability of 60, 37, and 36% in rats, dogs, and monkeys, respectively, with similar blood and plasma half-lives of approximately 20 h each. T1/2 value of GBT440 in all animal species is significantly shorter than the T1/2 of red blood cells (∼20 days), which supports that binding of GBT440 to hemoglobin is a reversible process. GBT440 is currently in Phase 3 clinical trials (NCT03036813) in SCD patients GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. In a murine model of SCD, GBT440 extends the half-life of RBCs, reduces reticulocyte counts and prevents ex vivo RBC sickling. Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute. GBT440 shows dose proportional PK, a terminal half-life of 1.5-3 d.


Cell Research(from reference)

Concentrations:0, 300, 600, 1000 μM 

Product Properties

ALogP2.7

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2D6 Tclin Cytochrome P450 2D6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C8 Tchem Cytochrome P450 2C8 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C19 Tchem Cytochrome P450 2C19 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C9 Tchem Cytochrome P450 2C9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HBB Tbio Hemoglobin subunit beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
INCHI InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
InChi Key FWCVZAQENIZVMY-UHFFFAOYSA-N
Canonical SMILES CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
Isomeric SMILES CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
PubChem CID 71602803
Molecular Weight 337.37

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

14 results found

Lot NumberCertificate TypeDateItem
F23061544Certificate of AnalysisApr 21, 2023 V414047
F23061554Certificate of AnalysisApr 21, 2023 V414047
F23061569Certificate of AnalysisApr 21, 2023 V414047
F23061604Certificate of AnalysisApr 21, 2023 V414047
F23061612Certificate of AnalysisApr 21, 2023 V414047
F23061983Certificate of AnalysisApr 21, 2023 V414047
F23061989Certificate of AnalysisApr 21, 2023 V414047
F23061992Certificate of AnalysisApr 21, 2023 V414047
F23062011Certificate of AnalysisApr 21, 2023 V414047
F23062022Certificate of AnalysisApr 21, 2023 V414047
F23062023Certificate of AnalysisApr 21, 2023 V414047
F23062037Certificate of AnalysisApr 21, 2023 V414047
F2306966Certificate of AnalysisApr 21, 2023 V414047
F2306967Certificate of AnalysisApr 21, 2023 V414047

more

Chemical and Physical Properties

SolubilityDMSO : ≥ 125 mg/mL (370.51 mM)

Related Documents

References

1. Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC et al..  (2019)  A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease..  N Engl J Med,  381  (6): (509-519).  [PMID:31199090]
2. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y et al..  (2017)  Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin..  ACS Med Chem Lett,  (3): (321-326).  [PMID:28337324]

Solution Calculators